Kinetic Analysis of Growth Activity in Enlarging Papillary Thyroid Microcarcinomas
Authors:
Open Access
- 16 December 2019
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 29 (12) , 1765-1773
Abstract
Background: Although papillary thyroid microcarcinoma (PMC) is generally stable on active surveillance, conversion surgery is recommended for enlarging tumors. However, it remains unclear which enlargement threshold should be considered sufficient to trigger surgery. This study analyzed changes in the growth activity of PMC, before and after enlargement. Methods: We enrolled 824 patients with PMC, in whom active surveillance was initiated between 2005 and 2011 (median duration of follow-up: 6.04 years). Changes in the maximal tumor size and tumor volume were evaluated. Point of enlargement (PE) was defined as the time at which maximal tumor size or tumor volume had increased by ≥3 mm (PE-M) or by ≥50% (PE-V), respectively. In patients with PMC who underwent at least three ultrasound examinations during the study period, we compared the tumor doubling rates (TDRs, designated as the inverse of doubling time) between pre- and post-PEs. Results: Ten-year enlargement-free survival rates based on maximal tumor size and tumor volume were 86.9% and 54.9%, respectively. The median post-PE TDRs was significantly lower than that of pre-PEs (−0.091/year vs. 0.509/year [ p < 0.001] for PE-M, and −0.058/year vs. 0.370/year [ p < 0.001] for PE-V), indicating decreased tumor growth after PEs. After PE-M and PE-V, the PMCs continued to rapidly enlarge (TDR >0.5/year) in only 6 (7.7%) and 11 (3.8%) patients and moderately enlarge (TDR 0.1–0.5/year) in 10 (12.8%) and 35 (12.1%) patients, respectively. Conversely, tumors shrank (TDR < −0.1/year) in 37 (47.4%) and 105 (36.1%) patients, respectively, and remained stable (TDR ranged between 0.1/year and −0.1/year) in 25 (32.1%) and 140 (48.1%) patients, respectively. Conclusion: Since most PMCs demonstrate a significant decrease in growth activity after enlargement, performing surgery immediately after the PE may be premature.Keywords
This publication has 16 references indexed in Scilit:
- Insights into the Management of Papillary Microcarcinoma of the ThyroidThyroid®, 2018
- Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the ThyroidWorld Journal of Surgery, 2016
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time‐Dependent Changes in Calcification and Vascularity During Active SurveillanceWorld Journal of Surgery, 2015
- Diminished WNT → β-catenin → c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumorsGenes & Development, 2014
- Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under ObservationThyroid®, 2014
- Therapeutic Strategy for Differentiated Thyroid Carcinoma in Japan Based on a Newly Established Guideline Managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine SurgeonsWorld Journal of Surgery, 2010
- Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and OutcomesWorld Journal of Surgery, 2010
- An Observational Trial for Papillary Thyroid Microcarcinoma in Japanese PatientsWorld Journal of Surgery, 2009
- An evolutionary model for initiation, promotion, and progression in carcinogenesisInternational Journal of Oncology, 2008